Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials

ObjectiveZolbetuximab is a “first-in-class” chimeric lgG1 monoclonal antibody targeting Claudin18.2 (CLDN 18.2). In recent years, several important trials have been published showing that zolbetuximab is associated with improved prognosis in patients with advanced gastric or gastro-esophageal juncti...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Zhanpeng Liang, Liwen Liu, Wenxia Li, Huiqin Lai, Luzhen Li, Jiaming Wu, Huatang Zhang, Cantu Fang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-10-01
Edice:	Frontiers in Oncology
Témata:	zolbetuximab Claudin18.2 gastric or gastro-oesophageal junction adenocarcinoma targeted therapy meta-analysis
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1258347/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!